January 22, 2019
The cold bucket of water is in the form of the upcoming splash of Q4 LPS (loss-per-share) earnings
… And cash positions re spending and “runways”
I’d start with enterprise value versus market cap disparities, return on equity, and short % of float, ATM utilizations and those companies that keep pushing payables and liabilities forward
Never forgetting regulatory status – the claim to a possible fame!
Pre-open indication: 1 BUY, 3 SELLs and 2 TRADEs
I answer one question, in which company should investors put, keep and commit their money!
January 22, 2019
EDIT (-$4.48 or -17.13%), Intellia Therapeutics (NTLA -$1.05 or -6.88%) and CRISPR Therapeutics (CRSP -$4.07 or -10.96%) equities plunged
EDIT volume is HIGH with 3.7 M shares traded <3 month average = 792.8 K shares, CRSP volume is also HIGH with 1.79 M shares traded <3 month average = 834.7 K shares> and NTLA volume is as LOWER with 577.05 K shares traded <3 month average = 694.3 K shares>
January 20, 2019
The mother of the sector relies on the future
In many companies, the upside share pricing history could be weakening!
Pre-open Indication: 3 HITs and 0 MISS
U.S. stock and bond markets on Monday will be closed in observance of the Martin Luther King Jr. holiday
Outspoken and just right again!
RMi outlines preludes and aftermaths defining the daily dose of facts, investment thesis and objectivity!
January 22, 2019
EDIT (-$4.48 or -17.13%), Intellia Therapeutics (NTLA -$1.05 or -6.88%) and CRISPR Therapeutics (CRSP -$4.07 or -10.96%) equities plunged EDIT volume is HIGH with 3.7 M shares traded <3 month average = 792.8 K shares, CRSP volume is also HIGH with 1.79 M shares traded <3 month average = 834.7 K shares> and NTLA volume is as LOWER with 577.05 K shares traded <3 month average = 694.3 K shares>
January 21, 2019
RMi is the source investors and traders need – it’s more than opinion; the facts and truth need to be recognized! I post about “indication intelligence” devoting my time to collection and analysis of information for insight into sector vulnerabilities and strengths. My writing is “that warning analysis is NOT a commodity. However, there are times, when the likelihood of conclusions are inescapable! http://www.regmedinvestors.com/create-account
January 16, 2019
STML closed up at $0.86 (+9.47%) to $9.94 Expected gross proceeds to Stemline are $80 million. Due to demand, this offering was upsized from the previously announced 6,600,000 shares. STML has also granted the underwriters a 30-day option to purchase up to 1,333,333 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. BUY
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
